Premium
Depression and its associated factors among people with multidrug‐resistant tuberculosis in Myanmar
Author(s) -
Theingi Phyo,
Kamiya Yasuhiko,
Myat Moe Myat,
Cho San Cho,
Cox Sharon E.
Publication year - 2021
Publication title -
tropical medicine and international health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.056
H-Index - 114
eISSN - 1365-3156
pISSN - 1360-2276
DOI - 10.1111/tmi.13637
Subject(s) - medicine , tuberculosis , depression (economics) , comorbidity , patient health questionnaire , logistic regression , psychological intervention , cross sectional study , depressive symptoms , diabetes mellitus , psychiatry , pathology , economics , macroeconomics , endocrinology
Background Depression is an important potential comorbidity in persons with tuberculosis (TB), yet data in many settings are scarce. Objective To estimate the prevalence and risk factors of depression in persons with multidrug‐resistant tuberculosis (MDR‐TB) in Myanmar. Methods A cross‐sectional survey among MDR‐TB participants at Aung San MDR‐TB treatment centre in Yangon during routine clinic follow‐up visits. Patients Health Questionnaire‐9 (PHQ‐9) in the local language was used to screen for depression and structured questionnaires conducted. Univariable and multivariable logistic regression models were performed to identify associations. Results Three‐hundred and twenty‐nine participants were enrolled between 19th December 2019 and 31st January 2020; 33% (111/329) in the intensive treatment phase. The prevalence of depressive symptoms (PHQ‐9 ≥ 10) was (34/329) 10.33%. Multivariable analysis indicated financial hardship as a result of MDR‐TB symptoms/treatment (aOR = 2.63, 95%CI: 1.12–6.67), suffering ≥1 respiratory symptoms (aOR = 6.72, 95%CI: 2.41–18.76), high education level (aOR = 4.26, 95%CI: 1.70–10.70), reported diabetes (aOR = 3.05, 95%CI: 1.16–7.99) as associated with depressive symptoms, with weak evidence of an association in females (aOR = 2.09, 95%CI: 0.94–4.65). Conclusion Depressive symptoms are more common in those with comorbidities/TB symptoms. Further research is required to determine the effects of interventions to support persons with depressive symptoms identified using simple, standardised validated tools like PHQ‐9.